Yu Noda

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki et al. · Cancers · 2020 · 78 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose et al. · Cancers · 2020 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Hideki Iwamoto, Shigeo Shimose, Yu Noda et al. · Cancers · 2021 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study

Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka et al. · Cancers · 2021 · 57 citations · Full text

Medicine, Oncology, Surgery +16

Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching

Shigeo Shimose, Masatoshi Tanaka, Hideki Iwamoto et al. · Hepatology Research · 2019 · 48 citations · Full text

Medicine, Oncology, Surgery +11